Block on Trump's Asylum Ban Upheld by Supreme Court
If you are close to someone who has recently been pregnant, you may have heard of noninvasive prenatal tests (NIPTs). These are a type of screening that use DNA from the fetus in a sample of a mother's blood to determine the baby's gender and if the baby is at risk for chromosomal abnormalities.
One laboratory providing this type of test claims that it provides "accurate, reliable results" and can help parents "create a confident plan." The idea is that the detection of an abnormality as early as 10 weeks into a pregnancy can help parents decide whether to terminate the pregnancy or start preparing to raise a child with a certain genetic condition. However, the fact that these tests are not subject to regulations by the Food and Drug Administration casts a shadow of doubt on these statements.
This blog discusses the history of NIPTs, reasons behind the lack of federal regulation, and the potential legal avenues for customers impacted by inaccurate test results.
NIPTs hit the market in 2011, after it was discovered that fetuses shed fragments of DNA into mothers' bloodstreams. Before that, the only way to learn genetic information about a fetus was through a process called amniocentesis, a more invasive procedure that utilized a three-inch needle to remove amniotic fluid from the uterus.
In 2012, only four laboratories offered NIPTs, mainly to mothers over the age of 35 and for the purposes of screening for Down syndrome. By 2019, the number of laboratories offering these tests had risen to over 40.
Today, NIPTs are being offered routinely to mothers of all ages and for an ever-growing list of genetic conditions. For example, the lab Natera now offers a test that screens for 25 genetic conditions. Nowadays, the American College of Obstetricians and Gynecologists (ACOG) recommends prenatal genetic screenings for "all pregnant patients regardless of maternal age or risk of chromosomal abnormality."
The global NIPT market was valued at $2.52 billion in 2020 and is expected to grow to $12.61 billion by 2031.
While NIPTs perform well at predicting relatively common conditions such as Down syndrome, the waters get murkier with predicting rarer conditions—such as DiGeorge syndrome, which affects one in every 4,000 births, and Prader-Willi syndrome, which affects one in 20,000. The New York Times reported that for DiGeorge syndrome, a positive result has an 81% chance of being wrong. For Prader-Willi, there's a 93% chance of a false positive. But most patient brochures do not even discuss the possibility of false positives.
Despite the fact that over a third of pregnant women in the U.S. undergo NIPTs, these tests are not regulated by the FDA. As lab-developed tests, NIPTs are outside the scope of the FDA's authority. Unlike FDA-regulated tests, NIPTs tests are not registered in a public database, product labeling is not reviewed or approved to ensure its comprehensiveness or accuracy, and there is no requirement for marketing claims to be supported by evidence. Furthermore, there is no government agency with the power to recall faulty tests.
The good news for patients (and their lawyers) is that a lack of FDA oversight does not necessarily mean a lack of accountability in the case of inaccurate test results.
Here are a few legal theories that may help affected patients get redress:
Meeting with a lawyer can help you understand your options and how to best protect your rights. Visit our attorney directory to find a lawyer near you who can help.
Sign into your Legal Forms and Services account to manage your estate planning documents.Sign In
Create an account allows to take advantage of these benefits: